dc.contributor.author | Efe, C | |
dc.contributor.author | Kulkarni, AV | |
dc.contributor.author | Beretta-Piccoli, BT | |
dc.contributor.author | Magro, B | |
dc.contributor.author | Stattermayer, AF | |
dc.contributor.author | Cengiz, M | |
dc.contributor.author | Clayton-Chubb, D | |
dc.contributor.author | Lammert, C | |
dc.contributor.author | Bernsmeier, C | |
dc.contributor.author | Gul, O | |
dc.contributor.author | Higuera-de la Tijera, FH | |
dc.contributor.author | Anders, M | |
dc.contributor.author | Lytvyak, E | |
dc.contributor.author | Akin, M | |
dc.contributor.author | Purnak, T | |
dc.contributor.author | Liberal, R | |
dc.contributor.author | Peralta, M | |
dc.contributor.author | Ebik, B | |
dc.contributor.author | Duman, S | |
dc.contributor.author | Demir, N | |
dc.contributor.author | Balaban, Y | |
dc.contributor.author | Urzua, A | |
dc.contributor.author | Contreras, F | |
dc.contributor.author | Venturelli, MG | |
dc.contributor.author | Bilgic, Y | |
dc.contributor.author | Medina, A | |
dc.contributor.author | Girala, M | |
dc.contributor.author | Gunsar, F | |
dc.contributor.author | Londono, MC | |
dc.contributor.author | Androutsakos, T | |
dc.contributor.author | Kisch, A | |
dc.contributor.author | Yurci, A | |
dc.contributor.author | Guzelbult, F | |
dc.contributor.author | Cagin, YF | |
dc.contributor.author | Avci, E | |
dc.contributor.author | Guzelbulut, M | |
dc.contributor.author | Dindar-Demiray, EK | |
dc.contributor.author | Harputluoglu, M | |
dc.contributor.author | Kumar, R | |
dc.contributor.author | Satapathy, SK | |
dc.contributor.author | Mendizabal, M | |
dc.contributor.author | Silva, M | |
dc.contributor.author | Fagiuoli, S | |
dc.contributor.author | Roberts, SK | |
dc.contributor.author | Soylu, NK | |
dc.contributor.author | Idilman, R | |
dc.contributor.author | Yoshida, EM | |
dc.contributor.author | Montano-Loza, AJ | |
dc.contributor.author | Dalekos, GN | |
dc.contributor.author | Ridruejo, E | |
dc.contributor.author | Schiano, TD | |
dc.contributor.author | Wahlin, S | |
dc.date.accessioned | 2023-01-02T08:53:12Z | |
dc.date.available | 2023-01-02T08:53:12Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | http://hdl.handle.net/11616/86986 | |
dc.description.abstract | Background and Aims A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury following SARS-CoV-2 vaccination in a large case series. Approach and Results We collected data from cases in 18 countries. The type of liver injury was assessed with the R-value. The study population was categorized according to features of immune-mediated hepatitis (positive autoantibodies and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury. We identified 87 patients (63%, female), median age 48 (range: 18-79) years at presentation. Liver injury was diagnosed a median 15 (range: 3-65) days after vaccination. Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases to the Moderna (mRNA-1273) vaccine. The liver injury was predominantly hepatocellular (84%) and 57% of patients showed features of immune-mediated hepatitis. Corticosteroids were given to 46 (53%) patients, more often for grade 3-4 liver injury than for grade 1-2 liver injury (88.9% vs. 43.5%, p = 0.001) and more often for patients with than without immune-mediated hepatitis (71.1% vs. 38.2%, p = 0.003). All patients showed resolution of liver injury except for one man (1.1%) who developed liver failure and underwent liver transplantation. Steroid therapy was withdrawn during the observation period in 12 (26%) patients after complete biochemical resolution. None had a relapse during follow-up. Conclusions SARS-CoV-2 vaccination can be associated with liver injury. Corticosteroid therapy may be beneficial in those with immune-mediated features or severe hepatitis. Outcome was generally favorable, but vaccine-associated liver injury led to fulminant liver failure in one patient. | |
dc.source | HEPATOLOGY | |
dc.title | Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated | |
dc.title | hepatitis, role of corticosteroid therapy and outcome |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |